CHARLESTON, South Carolina, March 11/PRNewswire/ --

- QualiLife Pharmaceuticals' Receives "Notice of Allowance of United States Patent" on Zestra for Women/Zestra Female Arousal Fluid

The only clinically-proven topical Female Arousal Fluid Zestra(TM) has received 'Notice of Allowance' from the United States Patent and Trademark Office just as Pfizer (NYSE:PFE) announced its decision to end Viagra(R) research in women. The race to develop what was previously termed a "female Viagra(R) equivalent" is over. QualiLife Pharmaceuticals, Inc., a privately-held consumer products company focused on Women's Health, has been developing Zestra since 1997, and it does not require a prescription.

The non-prescription Zestra patent is titled "Compositions and Method for Enhancing or Treating Female Sexual Response." Zestra from QualiLife Pharmaceuticals has demonstrated robust increases in female sexual arousal, pleasure and satisfaction in a well-designed, well-controlled clinical study conducted by several leading independent sexual medicine experts and scientists. The randomised, double-blind, placebo-controlled, crossover clinical study results are published in numerous respected medical journals.

Visit: www.zestraforwomen.com

"The approval of the Zestra patent is another milestone in QualiLife's strategy of utilising safe, effective bioactives from scientifically researched botanicals to provide clinically proven solutions for women," says pharmaceutical scientist and sexual medicine expert, Martin G. Crosby, R.Ph., its inventor. International patents are pending.

Published clinical study

Clinical study results for Zestra were first reported in Boston at the prestigious International Society for the Study of Women's Sexual Health (ISSWSH) and results are published in several respected medical journals --

The Journal of Sex & Marital Therapy, Drugs, National Association of Nurse Practitioners in Women's Health (NPWH) -- Women's Health Care: A Practical Journal for Nurse Practitioners, and WebMD Medical News.

http://www.zestraforwomen.com/aboutzestra/publications.html

Zestra Female Arousal Fluid is presently available for United States residents via online purchasing from the "Official Zestra for Women Website": www.zestraforwomen.com , and will be available in US Pharmacies in May 2004. QualiLife is seeking well-established European distribution and commercialisation partners.

Only Zestra was designed by pharmaceutical scientists and women's sexual health experts to effectively address the sexual pleasure pathways that are specific to women, says Crosby. "Non-prescription Zestra is the natural solution for most women who experience sexual problems such as difficulty with arousal, lubrication, sensation, pleasure, orgasm and satisfaction."

QualiLife's strategic focus

QualiLife is a Specialty Consumer Products company focused on satisfying large unmet needs by leveraging its proprietary research platform combined with pharmaceutical expertise in natural flavinoid technologies, biological precursor technologies, together with incorporation of highly-researched botanical bioactives having scientifically established activities and well- documented favourable safety profiles. While Zestra is QualiLife's flagship product, the Company has additional promising consumer products in late-stage development that address other large unmet needs in Women's Health.

QualiLife's proprietary targeted female libido solution is expected to join Zestra in the Company's consumer product line in October 2004. The Company continues to remain focused in Women's Health and seeks global commercialisation partners while exploring financing and/or merger options to maximise the Zestra and other pipeline opportunities.

Media contact:

Judith Lederman, JSL Publicity & Marketing

+1-914-472-9072 (phone)

+1-914-472-9073 (fax)

JudySL@aol.com (email)

Corporate contact:

Martin G. Crosby, R.Ph

President & CEO

QualiLife Pharmaceuticals, Inc.

+1-843-402-0901 (phone)

Web site: http://www.zestraforwomen.com/aboutzestra/mediaattention.html

http://americaslovedoctor.com/air.htm http://www.jslpublicity.com

http://www.zestraforwomen.com/aboutzestra/publications.html

http://www.zestraforwomen.com

Source: QualiLife Pharmaceuticals, Inc.

Judith Lederman of JSL Publicity & Marketing, +1-914-472-9072, or fax, +1-914-472-9073, or email, JudySL@aol.com; or Martin G. Crosby, R.Ph,, President & CEO of QualiLife Pharmaceuticals, Inc., +1-843-402-0901, or fax, +1-843-402-0919